IL-21

大会开幕倒计时3天2024.04.10BioCon China Expo 2024，第十一届国际生物药大会暨展览会，历经精心筹备，即将于2024年4月10-11日，在北京富力万丽酒店盛大开幕。此次大会汇聚了发改委、国内外知名药企、投资机构等众多行业领袖，加盟BioCon Expo 2024，共同探讨生物医药前沿话题。本届盛会为期两天，汇聚了包括“高层论坛”、“BD投融资新风口论坛”等20+场深度细分论坛，旨在聚焦生物医药领域的核心议题，进行深入研讨。同时，我们精心策划了商贸配对、闭门会议、BioCon Awards及投融资路演等一系列行业专属活动，更多精彩，等你探索！大会框架一览大会规模4月10-11日  北京富力万丽酒店5000+专业观众、170+ C-level VIP嘉宾70+赞助商/展商、20+专业买家组团150+商贸配对开幕式、闭门会、同期路演、BioCon Awards...精彩就位中！倒计时一周，报名通道即将关闭文末更有龙年大促活动两则，参与赢好礼！转发此推文，4月8日前报名即可享受：第2位  半价优惠第3位起 买1送1扫描上方二维码立即报名详情请联系组委会：131227855935000+知名企业嘉宾亮相参会热门议程抢先看，参会体验更精彩上下滑动🔽🔽🔽即可查看！高层论坛-国际生物医药产业风向标主持人：张宏翔，中国生物工程学会秘书长09:00 — 09:15主办方开幕致辞09:15 — 09:45十四五规划中国医药政策发展进展国家发展和改革委员会产业经济与技术经济研究所09:45 — 10:15国家科技计划项目管理政策进展解析中国生物技术发展中心10:15 — 10:452024全球生物医药发展趋势与机遇前瞻 胡奇聪，波士顿咨询董事总经理兼全球合伙人11:15 — 12:00圆桌讨论：道阻且长，行则将至，国产药出海的机遇与挑战√国际法规政策变化与趋势√加入PIC/S对于中国制药企业的影响√出海欧美VS新兴市场政策监管与市场考虑 主持人：徐增军，艾斯拓康生物医药有限公司，创始人、首席执行官；国家药品监督管理局药品审评中心，原首席科学家；美国食品药品管理局药品审评与研究中心新药办公室， 前资深审评官张连山，江苏恒瑞医药股份有限公司，董事、副总经理孙志刚，绿叶制药集团，高级副总裁Dinesh KHOKAL，新加坡卫生科学局前治疗产品部主任，Amgen前外部事务总监Rolf G. Werner，国际生物制药专家；德国图宾根大学名誉参议员兼教授；PharmaConsulting CEO12:00 — 12:45圆桌讨论：大药企创新战略升级与合作策略√跨国药企在中国的布局与合作机会寻找√国内药企创新转型中合作模式的变化√授权、投资、联合开发、兼并购等合作谈判的考量要点 主持人：张宇，中源协和细胞基因工程股份有限公司，副总经理、首席科学官；中源药业CEO黄丹洁，拜耳处方药事业部副总裁、中国合作创新中心负责人陈波，华润医药集团，首席科学家、科委会副主任姜非，康哲药业，首席投资官（大中华区）曹勇， 百济神州， 中国业务拓展副总裁高层论坛-产业战略热点前瞻14:00 — 14:45圆桌讨论：AI+跨界赋能医药创新的机遇与挑战√生成式AI等技术快速更新趋势√AI赋能科研、药物各阶段研发目前的挑战√从技术到商业落地，哪个应用将率先突围？√跨界行业纷纷入局，如何加强合作互信？主持人：杨剑飞，哲源科技有限公司，首席科学官邱婧君，复星医药，全球研发中心副总裁，生物统计与数据科学部总经理周一鸣，角井（北京）生物技术有限公司，创始人、董事长、CSO范梦奇，深势科技，生物医药事业群副总裁14:45 — 15:30圆桌讨论：未来生物医药生产布局：数字化、国产化替代趋势√生物制药的智能化数据系统等构建√连续化生产壁垒突破√数字化如何助力生产与降本增效√国产化替代趋势主持人：李树德，华润生物，首席制造官朱建伟，上海交通大学，“致远”讲席教授；杰科（天津）生物医药，创始人张丹，俄罗斯工程院，外籍院士；昆翎医药，联合创始人、首席战略官；谱新生物，联合创始人、联席董事长杨代常，武汉禾元生物科技股份有限公司，董事长15:30 — 16:15圆桌讨论：探讨医药CDMO产业的未来趋势：创新、合作与可持续√CDMO行业如何突破困境，开拓创新？√新的市场机遇趋势与产能突破机会探讨√结合客户、资金、人才、政策等多角度分析未来前景主持人：朱敏，浙江健新原力制药有限公司，高级副总裁何霆，北京希济生物科技有限公司，董事长刘伟，北京华龛生物科技有限公司，联合创始人&CEO高放，凯莱英生物，副总经理高晓伟，广州汉腾生物科技有限公司，运营副总裁BD投融资新风口与项目路演09:00 — 09:45圆桌讨论：穿越周期，未来3年中国的生物医药投融资方向与趋势几何？√资本寒冬，投资人们在看什么？√什么样的算是好项目？√资本风险的考量产生了哪些变化？√被投企业投后管理各家策略几何？主持人：余永平，鋆昊资本医疗基金合伙人；清华校友总会生命科学与医疗健康专委会秘书长郑玉芬，约印医疗基金创始人、董事长汤大杰，深圳前海勤智国际资本管理有限公司，董事长王曙光，上海文周投资管理有限公司，总经理柳丹，鼎晖投资，基金高级/管理合伙人邓灵泉，幂方健康基金，合伙人、SAPA全球董事09:45 — 12:15路演场次一、二详情请见下文中活动二：投融资项目路演。点击图片即可查看完整项目路演议程主持人：卢家琦，丁香园 Insight， BD 总监13:30 — 14:15圆桌讨论：买方视角：新的投融资环境下对 BD license in、战略投资、创新合作的挑战与对策分享主持人：季娟， 默沙东亚太业务拓展和授权中国区负责人边峰，百时美施贵宝全球药物研发执行总监、中国综合科学团队负责人徐亚南，武田中国，全球外部创新合作部中国区负责人俞颖慧，强生创新制药，全球BD中国区负责人牛颖，辉瑞投资有限公司，全球业务发展，中国搜索与评估负责人何灵，阿斯利康，中金医疗产业基金，董事总经理杨宏宽，维亚臻生物技术（上海）有限公司，高级BD总监李雯佳，罗氏制药，业务发展副总监14:15 — 15:00圆桌讨论：卖方视角：创新药license out成功的关键因素及交易风险的控制策略√ 成功交易背后考量哪些因素√法律风险如何考量√ IP 如何界定√ 出海交易风险主持人：刘毅铭，科律律师事务所，上海办事处主管合伙人戎一平，诺纳生物，联席CEO； 和铂医药，首席科学官任峰，英矽智能， Co-CEO & CSO吕璐璐，合源生物，首席执行官（CEO）郭俊慧，信达生物制药，Global BD中国区负责人吴晓东，鑫康合生物医药科技有限公司，商务运营副总裁15:30 — 16:15圆桌讨论：医药交易后联盟管理经验分享策划人与主持人：蒋志鹏，拜耳医药保健有限公司 ，战略联盟总监高建英，复星医药，副总裁、战略联盟管理部兼血液肿瘤市场部总经理黄静芳， 阿斯利康中国， 战略合作执行总监孙超，百济神州，高级总监，对外合作管理吴臻，意大利凯西医药，战略联盟总监张国财，华领医药技术（上海）有限公司，CEO商务助理兼集团业务拓展总监16:15 — 16:45大浪淘金，大环境变动下的医药交易江鹏，丁香园， Insight 数据库资深医药行业分析师突破重围：药企出海策略与实践主持人：李谦，弗若斯特沙利文，生命科学事业部咨询总监产品出海策略13:30 — 14:00利培酮缓释微球注射剂(Rykindo)美国获批案例分享 孙志刚，绿叶制药集团，高级副总裁14:00 — 14:30监管科学角度下的国际注册策略思考 程龙，荣昌生物，副总裁14:30 — 15:00全球布局：以未满足的临床需求为导向开发新抗体药物 陈兆荣，祐和医药科技（北京）有限公司，首席执行官 、首席医学官；百奥赛图（北京）医药科技股份有限公司，副总经理BD出海案例15:30 — 16:002023-2024创新药出海市场报告 毛化，弗若斯特沙利文，大中华区合伙人兼董事总经理16:00 — 16:30中国Biotech的ADC出海之路 肖亮（杨磊），苏州宜联生物医药有限公司，联合创始人、首席运营官国际化生产质控16:30 — 17:00产业视角：国际法规，质量和核查的趋势 Dinesh KHOKAL，新加坡卫生科学局前治疗产品部主任，Amgen前外部事务总监17:00 — 17:30MAH制度下，全球化的质量管理体系 许建辰，诺和诺德（中国）制药有限公司，监管政策和合规总监ADC与XDC药物全周期开发ADC创新研发与临床研究主持人：夏钢，浙江新码生物医药有限公司，CSO09:00 — 09:30淋巴瘤ADC药物的临床需求和临床研究进展 宋玉琴，北京大学肿瘤医院，副院长；淋巴肿瘤内科副主任，主任医师、教授、博士生导师09:30 — 10:00一种新的ADC策略：增强免疫检查点阻断疗法的抗肿瘤免疫反应 廖学斌，清华大学药学院，教授10:00 — 10:30ADC工艺稳定性开发和生物活性防护 陈湘东，楚天源创生物技术（长沙）有限公司，原液技术总监11:00 — 11:30Nectin-4ADC临床研发策略 王树海，迈威（上海）生物科技股份有限公司，首席医学官11:30 — 12:00ADC的定点偶联技术的优势和挑战 夏钢，浙江新码生物医药有限公司，CSO12:00 — 12:30双特异性ADC及天然IgG结构双抗平台的应用 陈克兰，凡恩世制药（北京）有限公司，副总裁ADC与XDC CMC开发与生产主持人：吴文哲，上海医药集团（本溪）北方药业有限公司，原液总监13:30 — 14:00放射性药物与放疗响应药物 刘志博，北京大学，教授14:00 — 14:30高效灌流培养：实现细胞培养效率与质量的双重提升 张鹏，富士胶片（中国）投资有限公司，技术经理14:30 — 15:00可遗传编码的蛋白质精准修饰技术及其在ADC制备中的应用 刘涛，北京大学，药学院教授，博导；分子与细胞药理系主任15:30 — 16:00ADC药物结构表征 王英武，长春金赛药业有限责任公司，生物药开发院，副院长16:00 — 16:30ADC早期研发中的要点实验和分析方法 梁贵合，睿智医药，抗体研发部总监16:30 — 17:00XDC药物工艺开发、转移与商业化生产 吴文哲，上海医药集团（本溪）北方药业有限公司，原液总监17:00 — 17:45圆桌讨论：ADC及XDC偶联药物的研发及工艺挑战主持人：刘涛，北京大学，药学院教授，博导，分子与细胞药理系主任刘志博，北京大学，教授唐艳旻，北京先通国际医药科技股份有限公司，Co-founder & CEO郭飞虎，天津恒瑞医药有限公司，总经理黄青，百力司康生物医药（杭州）有限公司，首席技术官、CTO史晋海，天津市滨海新区蛋白药物质量和产业技术创新研究会（原中国蛋白药物质量联盟）秘书长肿瘤免疫治疗研发与联合基于IO机制下的肿瘤新靶点及新分子开发主持人：朱建伟，上海交通大学，“致远”讲席教授；杰科（天津）生物医药，创始人09:00 — 09:30ADC与IO药物联合应用临床研究与展望 沈琳，北京大学肿瘤医院 消化内科主任、I期临床病区主任09:30 — 10:00基于抗体的融合蛋白的肿瘤免疫新策略New strategies of antibody based fusion proteins for tumor immunity傅阳心，清华大学医学院，讲席教授，清华大学肿瘤学科的带头人10:00 — 10:30Picodroplets for cell line engineering: a novel automation approach Romina Durigon, Senior Field Application Scientist，Sphere Fluidics11:00 — 11:30创新双功能免疫分子的设计及抗肿瘤研究 朱建伟，上海交通大学，“致远”讲席教授；杰科（天津）生物医药，创始人11:30 — 12:00靶向胞内抗原的TCRm药物研究进展 刘志刚，重庆智翔金泰生物制药股份有限公司，董事、首席科学官12:00 — 12:45圆桌讨论：未来肿瘤免疫治疗药物开发合作、联合治疗策略 主持人：李会铭，科兴生物制药股份有限公司，新药研究中心负责人、总经理沈琳，北京大学肿瘤医院 消化内科主任、I期临床病区主任傅阳心，清华大学医学院，讲席教授，清华大学肿瘤学科的带头人朱建伟，上海交通大学，“致远”讲席教授；杰科（天津）生物医药，创始人刘志刚，重庆智翔金泰生物制药股份有限公司，董事、首席科学官王明晗，凡恩世制药（北京）有限公司，创始人、首席执行官苗振伟，英百瑞(杭州)生物医药有限公司，董事长、总裁李江美，天广实生物技术股份有限公司，研发副总经理基于科学机制下的肿瘤免疫双多抗及联合治疗主持人：高新，免疫方舟创始人、CEO13:30 — 14:00IL-21靶向肿瘤特异性CD8+T细胞的免疫治疗策略研发及转化 王盛典，中国科学院生物物理研究所，研究员14:00 — 14:30DC-T cell Engager: 靶向CD40/4-1BB的双功能免疫激动剂 高新，免疫方舟创始人、CEO14:30 — 15:00A Novel anti-PD-1/IL2m fusion protein with enhanced therapeutic window for solid cancer treatment 李江美，天广实生物技术股份有限公司，研发副总经理15:30 — 16:00双特异抗体引导的NK,M∮细胞免疫治疗药物的开发 周海平，海徕科（北京）生物技术有限公司，CEO16:00 — 16:30TME myeloid biology肿瘤微环境中髓系细胞生物学研究 宁振飞，泽安生物医药，研发总监自免药物创新与开发主持人：杜云龙，北京普祺医药科技股份有限公司，CEO、CSO、合伙创始人9:00 — 9:30临床视角：自身免疫疾病未满足的临床需求及研究进展栗占国，北京大学人民医院风湿免疫科，主任医师、教授、博导；北京大学临床免疫中心，主任；北京大学医学部，风湿免疫学系主任9:30 — 10:00多学科交叉的自免生物技术药物创新张烜，北京医院，副院长；北京协和医学院，长聘教授兼临床免疫中心主任10:00 — 10:30免疫介导的炎症性疾病：机制研究和药物开发的新发现新进展陈波，华润医药集团，首席科学家、科委会副主任11:00 — 11:30IL-6R创新抗体药物的研发李自强，北京伟德杰生物科技有限公司，创始人、CEO11:30 — 12:00补体 C5a 靶点药物开发进展王超，舒泰神（北京）生物制药股份有限公司，总经理12:00 — 12:30单细胞数据驱动的自免疾病机制研究及药物开发吴琼，镁伽科技，AIDD负责人聚焦免疫调节和炎症靶点专注外用创新药研发杜云龙，北京普祺医药科技股份有限公司，CEO、CSO、合伙创始人mRNA药物全周期开发主持人：严景华，中国科学院微生物研究所，研究员09:00 — 09:30mRNA疫苗的质量控制研究 中国食品药品检定研究院专家09:30 — 10:00基于单链RNA噬菌体递送的双功能mRNA疫苗 童贻刚，北京化工大学，生命科学与技术学院院长10:00 — 10:30mRNA药物酶促合成与工艺相关杂质质控创新 李梁，瀚海新酶，事业合伙人/研发总监11:00 — 11:30抗体表征与疫苗设计 严景华，中国科学院微生物研究所，研究员11:30 — 12:00二价呼吸道合胞病毒mRNA疫苗研发进展 李惠，深信生物，R&D Director，Discovery12:00 — 12:30mRNA药物在病毒相关疾病防治中的应用与创新 岑山，仁景（苏州）生物科技有限公司，CSO核酸递送系统创新与开发主持人：葛啸虎，天津外泌体科技有限公司，董事长13:00 — 14:00改良ASO治疗肝癌的递送挑战杨振军，北京大学药学院教授，天然药物及仿生药物全国重点实验室课题组长14:00 — 14:30外泌体偶联技术及外泌体模块化制药新展望 葛啸虎，天津外泌体科技有限公司，董事长14:30 — 15:00PNI纳米颗粒制备技术应用解决方案 金毅，Cytiva 思拓凡，产品经理15:30 — 16:00针对不同组织的药物递送技术的创新与临床应用 臧晓羽，N1 Life, Inc. ，联合创始&CEO16:00 — 16:30靶向肿瘤环状RNA药物的设计合成与优化 谢震，清华大学，副教授16:30 — 17:15圆桌讨论：核酸疗法赛道日益火爆的现在，我们需要怎样“推陈出新”，走出自己独特的差异化优势？√新“赛道”：肿瘤/非肿瘤/罕见病/宠物疫苗/难以成药靶点/个性化治疗方案/环RNA√新“玩法“：应用于基因治疗/免疫细胞疗法/干细胞改造/靶向药研发√新“载具”：LNP载体优化/非LNP载体开发（复合物和聚合物纳米粒子、外泌体、生物微囊泡、偶联靶向分子）主持人：栗世铀，启辰生生物科技有限公司，联合创始人、CTO回爱民，惠正奇医药，创始人，董事长兼CE0；广州医科大学呼吸疾病国家重点实验室教授；中国生物医药产业链创新转化联合体副理事长刘健，康希诺生物(上海)有限公司，总经理谢震，清华大学，副教授葛啸虎，天津外泌体科技有限公司，董事长小核酸药物创新与开发主持人：万金桥，成都先衍生物技术有限公司，董事长，总经理，联合创始人小核酸药物临床试验设计与申报09:00-09:30慢性乙肝临床治愈——远未满足的临床需求 鲁凤民，北京大学感染病研究中心暨基础医学院病原生物学系主任09:30-10:00小干扰核酸（siRNA）药物临床开发策略与进展 尤冬，维亚臻生物技术（上海）有限公司，临床研发部负责人/医学执行副总裁10:00-10:30合成多肽纳米颗粒(PNP)用于递送小干扰核酸新药的临床进展 田伟伟，圣诺生物医药技术（苏州）有限公司，副总经理11:00-11:30差异化的小核酸新药临床前研发 万金桥，成都先衍生物技术有限公司，董事长，总经理，联合创始人11:30-12:15圆桌讨论：小核酸药物适应症的选择与开发策略 主持人：赵春林，安龙生物，创始人；安龙基金，创始合伙人鲁凤民，北京大学感染病研究中心暨基础医学院病原生物学系主任万金桥，成都先衍生物技术有限公司，董事长，总经理，联合创始人尤冬，维亚臻生物技术（上海）有限公司，临床研发部负责人/医学执行副总裁翟嘉洁，广东麦进嘉生物科技有限公司，首席执行官小核酸药物创新与CMC开发主持人：王海盛，思合基因，CEO13:30 — 14:00靶向RNA/蛋白的核酸药物研究 汤新景，北京大学，教授14:00 — 14:30核酸制药的关键挑战与研发进展 黄渊余，苏州炫景生物科技有限公司，创始人14:30 — 15:00小核酸肝外递送的探索 赵春林，安龙生物，创始人；安龙基金，创始合伙人15:00 — 15:30基于lncRNA的肝外递送研究与药物开发 宋旭，成都凌泰氪生物技术有限公司，创始人15:30 — 16:00单链寡核酸的新药研发--挑战与进展 王海盛，思合基因，CEO16:00 — 16:30小核酸药物的递送技术及CMC策略 黄泽傲，悦康药业集团股份有限公司，小核酸药物研发总监下一代CGT新赛道与源头创新未来药主持人：周德敏，北京大学，国家重点实验室主任、教授09:00 — 09:30化学精准修饰驱动的内源性物质成药性研究周德敏，北京大学，国家重点实验室主任、教授09:30 — 10:00帕金森病的细胞治疗陈志国，首都医科大学宣武医院细胞生物学研究室，主任；神经变性病教育部重点实验室，副主任、研究员、教授、博士生导师10:00 — 10:30原位神经再生最新进展，引领神经制药新赛道陈功，暨南大学大脑修复中心，主任；NeuExcell 神曦集团，创始人、首席科学家11:00 — 11:30设计新型tRNA药物治疗无义突变罕见病夏青，北京大学药学院，长聘教授11:30 — 12:00通用型双靶向抗体偶联NK细胞治疗开发苗振伟，英百瑞(杭州)生物医药有限公司，董事长、总裁12:00 — 12:30Bemiltenase alfa(STSP-0601)在血友病按需治疗中的研究探索 王超，舒泰神 (北京) 生物制药股份有限公司，总经理CGT 全生命周期质量管理与控制主持人：王永增，合源生物，CTO13:30 — 14:00建立全生命周期质量体系: DoE与QbD思路下的CGT产品开发案例王永增，合源生物，CTO14:00 — 14:30CGT中的细胞培养技术谭文松，上海倍谙基生物科技有限公司，创始人、董事长；华东理工大学生物工程学院、生物反应器工程国家重点实验室学科带头人；张江现代生物技术研究院，院长14:30 — 15:00细胞与基因治疗产品的病毒控制庞琳，北京昭衍药物检定研究有限公司，细胞毒种部总监15:30 — 16:00基因治疗产品的工艺开发与全过程质量控制策略欧阳文杰，深圳市禾沐基因生物技术有限责任公司，生产工艺部负责人16:00 — 16:30CAR-T 细胞疗法制造的产业化趋势Nolan Polson，BioCell Therapeutics总裁；GSK前战略产品质量副总裁；百时美施贵宝前细胞疗法全球产品质量总监（online）16:30 — 17:00微滴式数字PCR质粒拷贝数检测方法验证实践姚粟，中国工业微生物菌种保藏管理中心主任，中国微生物学会工业微生物专业委员会主任委员17:00 — 17:45圆桌讨论：CGT成本VS经济效益，未来CGT产业生态挑战与趋势主持人：许中伟，贝赛尔特（北京）及先进生物（苏州）有限公司创始人、董事长、首席科学家王永增，合源生物，CTO王歈，北京永泰生物制品有限公司，创始人、首席执行官、首席科技官范靖，浙江霍德生物工程有限公司创始人、CEO17:45-18:15实现以患者为中心规范的新型细胞疗法控制策略 Nolan Polson，BioCell Therapeutics总裁；GSK前战略产品质量副总裁；百时美施贵宝前细胞疗法全球产品质量总监（online）细胞基因治疗商业化主持人：李洁，中国药品监督管理研究会细胞与基因治疗产品监管研究专业委员会副主任委员、瓴路药业顾问09:00 — 09:30细胞免疫疗法在临床治疗中的标准化探索韩为东，中国人民解放军总医院生物治疗科，主任09:30 — 10:00基因治疗中国商业化探索李正斌，纽福斯生物科技有限公司，副总裁10:00 — 10:30CAR-T产品的中国商业化之路齐渊元，复星凯特生物科技有限公司，首席商务官11:00 — 11:45圆桌讨论：如何以患者为中心，使更多的患者能用得上细胞基因疗法？√医保/商业保险/公益组织如何合作，减少患者经济负担√临床层面：提升医院的治疗信心？√肿瘤及非肿瘤商业可及性的考量主持人：王小宁，解放军总医院暨全军老年医学研究所原所长，国家老年疾病临床中心副主任李洁，中国药品监督管理研究会细胞与基因治疗产品监管研究专委会副主任委员齐渊元，复星凯特生物科技有限公司，首席商务官李正斌，纽福斯生物科技有限公司，副总裁谢祖全，信念医药，商务管理副总裁刘博锋，陆道培医院国际中心，主任CGT临床研发与申报主持人：韩成权，北京诺思兰德生物技术股份有限公司，副总裁、董事13:30 — 14:00细胞基因治疗安全性及长期效应验证和评估策略高晨燕，昌平实验室，资深科学家14:00 — 14:30早期CGT技术开发与临床试验策略分享李宁，国家癌症中心/中国医学科学院肿瘤医院，副院长 14:30 — 15:00眼科基因治疗各阶段临床试验设计探索陈有信，北京协和医院眼科，教授，眼底病重点实验室主任15:30 — 16:00全球创新现货通用性DNT细胞药的临床开发与进展杨黎明，瑞顺生物，创始人、董事长、首席科学官16:00 — 16:30临床级iPS衍生细胞药治疗帕金森病等重大神经系统疾病李翔，士泽生物医药（苏州）有限公司，创始人、董事长、CEO、CSO16:30 — 17:00自体靶向细胞治疗临床试验设计思考与实践张翩，恒瑞源正，临床中心VP17:00 — 17:30首个裸质粒基因治疗药物的III期临床试验初步结果韩成权，北京诺思兰德生物技术股份有限公司，副总裁、董事GLP-1相关多肽药物创新与开发主持人：张龙，德睿智药，联合创始人09:00 — 09:30小分子GLP-1多重激动剂创新药研究徐华强，中国科学院上海药物研究所 研究员/博士生导师 ，原创新药研究全国重点实验室 副主任，中科院上海药物研究所药物靶标结构与功能中心 主任09:30 — 10:00联邦生物GLP-1R/GIPR/GCGR三靶点激动剂的开发曹春来，联邦生物科技（珠海横琴）有限公司，总经理曹春来，联邦生物科技（珠海横琴）有限公司，总经理10:00 — 10:30合成肽药物药学研究的关注点李新宇，深圳市健元医药科技有限公司副总经理11:00 — 11:30GLP1R激动剂的前沿进展和未来方向：寻找下一个“药王”张龙，德睿智药，联合创始人11:30 — 12:15圆桌讨论：GLP1火爆依旧，国内差异化竞争/差异化研发何去何从主持人：张龙，德睿智药，联合创始人曹春来，联邦生物科技（珠海横琴）有限公司，总经理方永亮，浙江道尔生物有限公司，首席运营官王雷，北京拓界生物，总经理主持人：方永亮，浙江道尔生物有限公司，首席运营官13:30 — 14:00创新型靶向GLP-1R/GIPR的双靶点激动剂的发现和临床转化方永亮，浙江道尔生物有限公司，首席运营官14:00 — 14:30多靶点GLP-1类多肽新药开发王雷，北京拓界生物，总经理14:30 — 15:00PDC药物研究进展徐寒梅，中国药科大学，教授（博导）；海洋药学专业负责人；江苏省合成多肽药物发现与评价工程中心，主任15:30 — 16:00基于生存策略的动物毒素多肽新药开发容明强，成都佩德生物医药有限公司，董事长16:00 — 16:30基于C-C键形成的环肽构建及多肽偶联药物设计方向新进展朱勍，浙江工业大学，教授前沿药物递送与制剂创新9:00 — 9:30先进药物递释系统：创新与转化顾臻，浙江大学，求是讲席教授，药学院院长；金华研究院，院长9:30 — 10:00纳米药物高端制剂体系的研发转化聚焦及突破梁兴杰，中国科学院大学纳米科技学院纳米生物学首席讲座教授；中科院纳米科学卓越中心纳米药物团队负责人；国家纳米科学中心可控纳米药物学实验室主任10:00 — 10:30我国高端制剂从基础研究向应用转化的战略思考陆伟跃，复旦大学特聘教授，药剂学博士11:00 — 11:30小分子偶联新药研发贺耘，深圳湾实验室，百瑞创新中心主任11:30 — 12:00核酸药物的吸入递送侯曙光，成都中医药大学，首席教授12:00 — 12:30基于智能分子桥接的核酸药物递送研究孙敏捷，中国药科大学，教授高端与改良制剂的开发与产业化13:30 — 14:00难溶性药物的制剂策略韩军，聊城大学生物制药研究院 院长、教授14:00 — 14:30可注射长效制剂的开发史亚楠，烟台大学，教授14:30 — 15:00BCS、DCS、BDDCS在口服制剂研发中的应用刘恒利，凯信远达医药，研发部门负责人15:30 — 16:00脂质原位凝胶技术在改良型新药中的应用和案例解析佐建锋，燃点（南京）生物医药科技有限公司，副总经理* 更新截止于4月9日前，以展会现场为准闭门会与时代同行，逐未来之翼闭门会（定向邀约制）9:30-12:00  BD合作与对接闭门会DAY2 (4月11日) 富力8&9主持人：毛化，弗若斯特沙利文，大中华区合伙人兼董事总经理闭门会背景:2023年是中国生物医药行业跌宕起伏的一年，不仅面临着资本寒冬、内卷严重、人才缺失等问题，与此同时也在出海方面喜讯连连，合作数量的数量方面均有大幅提升。2024年的生物医药行业又将面临怎样的机遇和挑战?如何在出海新浪潮下把握企业前行的航向?如何应对生物医药的投资压力并找到破局之法?如何提高资金配置效率?为此，作为与第十一届 BioCon China Expo 2024 的同期活动，商图将于2024年4月11日上午同期组织一场BioCon Expo 2024 闭门会，探讨中国生物医药在商业化和出海方面面临的一些机遇和挑战。参会群体:跨国药企、本土药企、创新药企以及围绕BD交易赋能的投资机构/政府/律所/CRO/CDMO/咨询等机构的CEO、高管、合伙人等12:00-14:00 细胞治疗临床研究推广困境与对策DAY2 (4月11日) 富力8&9牵头人：王小宁，解放军总医院暨全军老年医学研究所原所长，国家老年疾病临床中心副主任闭门会背景:根据世卫组织与国际癌症研究机构发布的全球最新癌症数据均显示我国的癌症患者新发与死亡人数位居全球第一。  CAR-T作为目前最有发展前景的CGT疗法之一,在肿瘤的治疗中已取得重大突破。弗若斯特沙利文研究机构预测，中国仅CAR-T市场的规模预计到2030年将达到289亿元。然而，“好药难卖”，“价格高昂”，“缺乏互信”“临床管理”是横在我国CGT药企、患者、医生之间的巨大鸿沟。那么，我们该如何使更多的患者能够用得上、用得起CGT产品呢？为此，由解放军总医院暨全军老年医学研究所原所长，国家老年疾病临床中心副主任王小宁教授牵头，本次闭门会汇聚了CGT领域的：企业、医生、监管、保险等领域的专家老师们，期待能够推动我国CGT临床治疗，使更多的患者受益。四大精彩活动，等你开启惊喜瞬间01一对一商务约见离成功更近一步为方便您约见核心商务伙伴，高效对接，促进深度合作与交流，本次大会特别提供1v1商务约见服务。高效约见合作伙伴，拓人脉资源，挖掘合作机会。扫码立即登入约见系统*注：4月9日前注册的嘉宾可以通过注册时的手机号登录1v1商务约见系统，配对成功后您可以查看对方的联系方式相约见面，我们也准备了位于【首府厅3-2】商务洽谈区供您使用（部分时间开放）点击下方图片，即可查看详细约见步骤02投融资项目路演加速实现成果转化2023年资本市场更趋理性，医药大健康行业IPO与再融资收紧，但投资并购活跃，国资积极参与整合与转型，药企面临资本寒冬，需寻新出路。为更好促进生物制药行业交流，加快创新团队成长与成果转化，BioCon ChinaExpo 2024组委特设现场同期【投融资】项目路演活动。自BioCon China Expo现场路演面向生物制药行业企业展开征集后，已经收到行业50+家企业的积极响应与热情参与！在经过组委以及投资人评委的审慎评选后，项目路演活动议程正式出炉。快来现场为你看好的项目打call吧！点击下方图片，即可查看项目路演详细议程及更多相关信息03医药人职业说职等你来数十家优秀企业在“才聚一堂”招聘墙发布专业人才招聘需求，覆盖多个岗位，助力企业和人才牵手成功!在众多医药人欢聚一堂之际，本次大会特别联合诗迈医药联合策划了一场“医药人职业说”分享会，邀请了多位医药领域人才专家从不同角度分享医药人才环境、职业规划等备受关注的内容，以期为大家提供宝贵的借鉴与启示。时间：4月10日下午地点：【首府厅3-1】*注:招聘信息墙也会在此一同展出点击下方图片，即可立即参与活动或查看更多详细内容04BioCon Awards 颁奖典礼覆盖产业全周期的权威行业奖项2023年中国生物医药行业面临，同质化竞争、行业内卷等困难，但展望2024年，行业有望在全体生物医药人的努力下取得新突破。BioConAwards2024作为生物医药行业的品牌赛事，已全面升级，汇集业内权威专家组成专业评审阵容，从多个维度公平、公正地评选出来自生物技术行业各个领域的先锋企业/组织/个人代表。BioCon Awards五大奖项自报名通道开启以来，便得到了生物技术领域众多人士的热烈反响和踊跃参与。今年，我们欣喜地看到，参奖数量已远超去年，这充分展示了行业内的活力与创新精神，对此我们表示衷心的感谢。投票已截至，激动人心的时刻即将来临。我们诚挚地邀请大家，共聚颁奖典礼，来现场见证结果揭晓！(最终评选结果将会在“奖项公布墙”展示，请前往【富力厅1&2】对面查看)颁奖典礼时间：4月10日下午16:15-17:15地点：【富力厅1&2】点击下方图片，即可立即查看奖项详细信息特别鸣谢以下合作单位鼎力支持Special Thanks合作单位赞助单位媒体单位参与活动领好礼！龙年大促活动一：转发指定推文集赞转发赢取好礼！① 门票大赠送：转发本推文至朋友圈，集赞30位或转发生物医药技术行业群（规模≥100人）5个，赠送价值2390元会场通票（不含餐），添加微信131 2278 5593联系工作人员领取；Ps：活动仅面向药企与科研机构专业人员，若有升级VIP需求可联系组委会单独购买② 升级礼包好运抽：现场签到凭转发朋友圈或行业群截图，抽取幸运好礼，中奖率100%！更可抽到价值2000元VIP升级礼包（包含2天自助午餐及VIP参会礼包）。龙年大促活动二：限时团报更优惠！① 邀请好友一起参加Biocon Expo 2024，第2位半价优惠！第3位起买1送1！② 3人以上组团购买门票，即可每人现场领取30元京东卡！Ps：时间截止到4月8日。联系组委会BioCon咨询参展/赞助/参会电话:+86 131 2278 5593邮箱: biocon@bmapglobal.com

WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21 INDUKINETM molecule has potent antitumor activity in preclinical models with a differentiated immune activation mechanism WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally-activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California. “We are excited to share that both WTX-518 and WTX-712 demonstrate powerful immunotherapeutic effects in preclinical models,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “WTX-518 exhibits remarkable tumor-selective activation, resistance to IL-18BP and robust immune activation, overcoming key hurdles in the use of this promising cytokine in cancer therapy. WTX-712 acts through a unique mechanism that robustly activates tumor-specific T lymphocytes with an expanded therapeutic window through its selective release of wild-type IL-21 in the TME. These data collectively highlight the innovative strategies we are pursuing to further expand the repertoire of unique immune stimulating cytokine mechanisms in the fight against cancer.” Results highlighting WTX-518 findings are summarized in a poster titled, “Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models” (Abstract #4074). Key takeaways reveal that WTX-518: is inducible, and its in vitro activity is not impeded by IL-18BP; selectively delivers active binding protein resistant (BPR) IL-18 to the tumor microenvironment (TME); and promotes increased influx and activation of NK cells and polyfunctional CD8 T cells in the TME, and demonstrates complete tumor regression in the MC38 mouse tumor model. The WTX-712 data are summarized in a poster titled, “WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanism” (Abstract #4078). Key takeaways reveal that: WTX-712 demonstrates inducibility and antitumor activity with regressions in the MC38 mouse tumor model; IL-21 HLE (half-life extended) has superior anti-tumor efficacy compared to IL-2 HLE therapy in mouse tumor models that are highly resistant to anti-PD-1/PD-L1 treatment, in part due to the activation of type-I IFN pathways; and IL-21 HLE promotes sustained expansion and activation of tumor infiltrating CD8 T cells with increased polyfunctionality and induces expression of cytotoxic effector molecules (Granzyme A, Granzyme B, and perforin). Both posters can be viewed in person from 9:00 a.m. to 12:30 p.m. PDT on Tuesday, April 9, during the session category “Immunology” at Poster Section 4, and will be available on our website at Werewolf plans to develop WTX-518 and WTX-712 as potential immunotherapies in refractory and/or immunologically unresponsive tumors. About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s future operations, prospects, plans, and the potential activity and efficacy of product candidates in preclinical studies constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; the Company’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on the Company’s business and operations; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (“SEC”), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Investor Contact: Josh Rappaport Stern IR 212.362.1200 Josh.Rappaport@sternir.com Media Contact: Amanda Sellers VERGE Scientific Communications 301.332.5574 asellers@vergescientific.com Company Contact: Ellen Lubman Chief Business Officer Werewolf Therapeutics elubman@werewolftx.com

­-- AB248 demonstrates over 500-fold preference for CD8+ T cells compared to other cell types; selectivity intended to optimize efficacy and mitigate toxicities observed with broadly acting IL-2 therapies – -- In variety of preclinical models, AB248 demonstrates improved anti-tumor activity and reduced toxicity compared to untargeted “not-α”IL-2, as well as the ability to reinvigorate dysfunctional T cells -- -- Preclinical data support evaluation of AB248 as monotherapy and in combination with an anti-PD-1 inhibitor in an ongoing Phase 1a/1b clinical trial in locally advanced or metastatic solid tumors -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the publication of two manuscripts in Cancer Discovery, a journal of the American Association for Cancer Research, detailing the design of AB248 and reviewing preclinical data supporting its development as a potentially best-in-class interleukin-2 (IL-2) therapy. The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024. “We are delighted to announce the publication of preclinical data on AB248, our lead product candidate for the treatment of solid tumors, in a prestigious cancer research and medicine journal”, said Andy Yeung, Chief Technology Officer of Asher Bio. “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr. Ton Schumacher, of NKI, and Dr. Robert Schreiber, of Washington University School of Medicine, alongside our collaborator, Dr. Daniela Thommen, of NKI.” “With AB248, we set out to solve a major limitation of existing immune-based medicines – namely, the significant off-target effects that come from acting on multiple cell types simultaneously”, commented Ivana Djuretic, Chief Scientific Officer of Asher Bio. “AB248 was designed to potently and selectively activate CD8+ T cells, which are responsible for driving anti-tumor activity, while avoiding NK cells and Tregs, which can act as a pharmacological sink, contribute to toxicities, and suppress the immune system more broadly. Preclinical data from the Asher Bio, Schreiber and Thommen labs together reinforce the power of AB248’s highly differentiated profile, showing an unprecedented level of selectivity for CD8+ T cells, as well as enhanced anti-tumor activity and improved tolerability, and further support the evaluation of AB248 in our ongoing Phase 1a/1b trial.” Preclinical Data Suggest AB248 Offers Improved Therapeutic Index and CD8+ T Cell Selectivity In the first publication entitled, “CD8+ T cell-targeted IL-2 promotes robust effector T cell responses to mediate potent anti-tumor immunity,” lead author Dr. Kelly Moynihan, Ph.D., Senior Director and Project Team Leader at Asher Bio, described the rationale for, and the design of, AB248, and reviewed nonclinical data suggesting AB248 offers an improved therapeutic index compared to broadly acting IL-2-based therapies. While high dose IL-2 therapy is approved for the treatment of certain cancers, its clinical use is limited due to life-threatening toxicities. A next generation of IL-2 therapies, “not-α” IL-2s, were subsequently introduced to mitigate some of the liabilities associated with high dose IL-2 through binding the IL-2 α receptor, such as potent regulatory T cell (Treg) stimulation and vascular leak syndrome (VLS). To-date, however, these “not-α” IL-2 have not demonstrated a meaningful improvement in clinical efficacy and, while VLS appears mitigated, significant toxicities still occur. In preclinical studies, natural killer (NK) cells were responsible for toxicities following treatment with a not-α IL-2 therapy but did not contribute to anti-tumor activity. Asher Bio hypothesized that the therapeutic index of an IL-2 therapy could be improved by selectively targeting CD8+ T cells – which are critical effectors of antitumor immunity – while avoiding other cell types, such as non-specific, innate NK cells and immunosuppressive Treg cells. Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2. AB248 recapitulates key features of IL-2 biology, including induction of proliferation and enhancement of effector function, but does so selectively in CD8+ T cells across a wide range of concentrations in vitro and in vivo, with over 500-fold preference for CD8+ T cells compared to other cell types. Preclinical data demonstrate the potential of a CD8+ T cell selective IL-2 to improve the therapeutic index of IL-2 and support the advancement of AB248 into the clinic: - In preclinical mouse models, a single dose of AB248’s murine surrogate (CD8-mIL2) demonstrated strongly improved anti-tumor activity and reduced toxicity compared to untargeted not-α IL-2 variants. - Further, CD8-mIL2 drastically increased the number and function of tumor antigen specific T cells and induced a “better effector” population, with a signature consistent with high polyfunctionality and low exhaustion. - Activity depended both on tumor-resident as well as newly infiltrating T cells on therapy. - In non-human primates, treatment with AB248 induced potent and selective CD8+ T cell expansion. Treatment was generally well tolerated despite expansion of CD8+ T cells by 20-fold or more. In summary, AB248 achieved substantial improvements in IL-2’s therapeutic index by selectively targeting all CD8+ T cells without the need to restrict signaling to the tumor site or a single CD8+ T cell subset. Preclinical Data Support Evaluation of AB248 in Combination with Anti-PD-1 Therapy In a paper entitled, “CD8-targeted IL-2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T cell pool,” lead author Paulien Kaptein, Division of Molecular Oncology and Immunology at the NKI, reported new preclinical data supporting the evaluation of AB248 in combination with an immune checkpoint inhibitor in models utilizing ex vivo human tumor tissues from patients. T cell-based immunotherapies are a groundbreaking approach to treating some cancers. However, a considerable portion of tumors characterized by T cell infiltration remain unresponsive to immune checkpoint blockade (ICB), suggesting a need for novel strategies to restore effector activity in tumor specific T cells. IL-2-based therapies have been identified as a promising strategy for enhancing T cell responses in ICB-resistant tumors. To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248. Data show: - Treatment with AB248 broadly armed human intratumoral CD8+ T cells with enhanced effector capacity, specifically enabling reinvigoration of the dysfunctional T cell pool to elicit potent immune activity. - Tumor-specific T cells underwent broader and qualitatively superior activation with AB248 treatment compared to programmed death-1 (PD-1) blockade. - AB248 generated an immunological response in tumors that did not show an immunological response to anti-PD-1, suggesting the presence of a tumor-reactive T cell pool targetable by AB248 that is not responsive to PD-1 blockade alone. - Treatment with AB248 in combination with anti-PD-1 resulted in greater ex vivo responses, supporting the combination of AB248 and anti-PD-1 clinically. “While immune checkpoint inhibitors are an incredibly powerful tool for treating certain cancers, many tumors don’t respond, underscoring the need for new agents that can reinvigorate exhausted T cells and make them susceptible to PD-1 blockade,” said Daniela Thommen, M.D., Ph.D., Group Leader, Department of Molecular Oncology and Immunology at the Netherlands Cancer Institute and senior author on the NKI publication. “New preclinical data published today suggest that treatment with AB248 may stimulate T cells within tumors otherwise resistant to PD-1 therapy, offering a combination strategy that may extend the reach of immuno-oncology regimens across a range of solid tumors. I look forward to initial clinical data from Asher Bio’s ongoing Phase 1a/1b clinical trial, which includes a cohort evaluating AB248 in combination with an anti-PD-1 therapy.” Both publications are now available online through Cancer Discovery: . About AB248 AB248 is a novel CD8+ T cell selective IL-2, generated by fusing a reduced potency IL-2 mutein to an anti-CD8β antibody. It was specifically engineered to selectively and potently activate CD8+ T-cells, while avoiding natural killer (NK) cells, which can act as a pharmacological sink and contribute to toxicity, and regulatory T (Treg) cells, which are immunosuppressive. In preclinical studies, AB248 exhibited an approximately 1,000-fold preference for the activation of CD8+ T cells over NK cells and Tregs. In preclinical murine tumor studies, AB248 demonstrated potent anti-tumor activity both alone and in combination with PD-1 checkpoint blockade in a wide variety of murine tumor models. Asher Bio is currently evaluating AB248 in a Phase 1a/1b clinical trial, AB248-101. The trial consists of a dose escalation and expansion phase to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of AB248 alone and in combination with pembrolizumab in subjects with locally advanced/metastatic solid tumors who failed prior therapies. Please refer to (NCT05653882) for additional details related to this Phase 1a/1b clinical trial. About Asher Bio Asher Bio is a biotechnology company developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Our lead program AB248, an IL-2 molecule specifically targeted to CD8+ effector T cells, is currently in Phase 1 trials for oncology. Our broader portfolio includes AB821, an IND-ready CD8-targeted IL-21 immunotherapy, and early-stage programs targeting CAR-T cells, myeloid cells and CD4+ T cells. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit and follow us on X (formerly Twitter) @AsherBio and on LinkedIn.